Clinical Report: Next-Generation Spectacle Lens Aims to Strengthen Myopia Control in Children

Overview

Essilor has launched the Stellest 2.0 lens, designed to enhance myopia control in children by refining optical design. Clinical trials indicate a significant reduction in axial elongation compared to the original Stellest lens.

Background

The prevalence of childhood myopia is rising globally, raising concerns about long-term ocular health risks. Myopia management strategies are increasingly important as they aim to slow axial elongation rather than merely correct refractive errors. Innovative optical interventions, such as the Stellest 2.0 lens, represent a non-invasive approach to managing this condition in pediatric patients.

Data Highlights

Key Findings

• Stellest 2.0 incorporates H.A.L.T. MAX technology to enhance optical power and asphericity.
• The updated lens design includes 12 concentric rings of lenslets, improving upon the previous version's 11 rings.
• Clinical trials indicated a significant reduction in axial elongation in children wearing Stellest 2.0 lenses.
• Younger children, particularly those aged 8.5 years or younger, may benefit more from the new lens design.
• The lenses maintain visual clarity and impact resistance similar to earlier Stellest products.

Clinical Implications

Clinicians should communicate the importance of myopia management to families, emphasizing that standard lenses do not slow myopia progression. Early intervention is crucial for children at risk of rapid myopia progression.

Conclusion

The introduction of Stellest 2.0 represents a significant advancement in non-invasive myopia management for children, with promising clinical trial results supporting its efficacy.

Related Resources & Content

1. Essilor, Optometric Management, 2023 -- Next-Generation Spectacle Lens Aims to Strengthen Myopia Control in Children
2. Andrew D. Pucker, Optometric Management, 2023 -- Myopia Control Spectacles: Review of the Latest Research
3. Maria Liu, Optometric Management, 2024 -- MYOPIA: Reviewing proposed mechanisms for myopia spectacles
4. FDA, FDA, 2025 -- FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia
5. Optometric Management — BUSINESS: Optical
6. optometric management — Myopia: Spectacle Lens Use
7. Efficacy of spectacle lenses for myopia control: a meta-analysis of randomised controlled trials
8. IMI-Instrumentation for Myopia Management
9. FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia | FDA